Table 2.
Pharmacokinetic parameters of HAP-ELPs determined through various routes of administration.
| HAP-A96 | HAP-V96 | |
|---|---|---|
| Supra-lacrimal gland Administration | ||
| Dose (nanomoles) | 37.5 | 37.5 |
| Mouse weight (g) | 29.3 (2.2) | 30.3 (1.3) |
| IVIS parameters | ||
| AUC (signal x h) | 1510 (30) | 16,000 (8400) |
| AUMC (signal x h2) | 18,500 (800) | 1,300,000 (800,000) |
| MRT (h) | 12.3 (0.6) | 81 (49) |
| Plasma parameters | ||
| MRTLG (h) | 67.8 (17.9) | * |
| AUCLG (μM x h) | 4.7 (0.4) | * |
| CL/F (mL/h) | 8.1 (0.8) | * |
| Cmax (μM) | 0.35 (0.03) | * |
| Tmax (h) | 4.3 (2.5) | * |
| t1/2 (h) | 22.0 (3.6) | * |
| Intravenous Bolus Administration | ||
| Dose (nanomoles) | 5 | * |
| Mouse weight (g) | 29.3 (1.5) | * |
| Plasma parameters | ||
| Vd (mL) | 14.9 (8.3) | * |
| Vss (mL) | 23.9 (13.4) | * |
| MRTIV (h) | 10.4 (5.3) | * |
| AUCIV (μM x h) | 2.3 (0.2) | * |
| CL (mL/h) | 2.2 (0.2) | * |
| t1/2 (h) | 19.2 (6.2) | * |
| Combined Parameters | ||
| MAT (h) | 57.4 (18.7) | * |
| Bioavailability (%) | 27.7 (2.5) | * |
Values are indicated as mean (SD).
*
Measured plasma concentrations were below the lower limit of quantification